Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Yufei Shi has a total of 246 co-authors. Here are the top co-authors by number of shared publications:

  • Minjing Zou

    Innovation and Research, King Faisal Specialist Hospital & Research Centre, Riyadh, Saudi Arabia

    53 shared publications
  • Brian F. Meyer

    Department of Molecular Oncology, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia

    16 shared publications
  • Ali S. Alzahrani

    Department of Medicine, King Faisal Specialist Hospital and Research Centre , Riyadh 11211

    15 shared publications
  • Nadir R. Farid

    Department of Genetics Osancor Biotech Inc WD17 4EJ Watford Herts UK

    15 shared publications
  • Ali S. Alzahrani

    Medicine, King Faisal Specialist Hospital & Research Centre, Riyadh, Saudi Arabia

    14 shared publications
  • Essa Y. Baitei

    Department of Genetics, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia

    14 shared publications

Latest Publications

  • Open Access

    SGK3 promoter deletion in late-onset hypophosphatemic rickets, a possible genetic cause of the disease

    by Ahmet Uçar, Najla Albader, Amal Qattan, Huda A. BinEssa, Ebru Mısırlı Özdemir, Mustafa Özdemir, Minjing Zou, Ali S. Alzahrani, Yufei Shi

    Background: Hypophosphataemic rickets (HR) is a group of rare hereditary renal phosphate wasting disorders caused by mutations in the PHEX , FGF23 , DMP1 , ENPP1 , CLCN5 , SGK3, SLC9A3R1 , SLC34A1 or SLC34A3 . Objective: To identify the genetic defects in a patient with late-onset hypophosphatemia. Subjects: A 15-year old boy with hypophosphatemic rickets, his unaffected parents and 7 siblings. Design: Patients and their family members were initially analyzed for PHEX and FGF23 mutations by PCR-sequencing analysis. Exome and whole-genome sequencing were subsequently performed to identify causative genetic defects. Results: The patient was normal until the age of 11 years old. He presented with severe rickets, hypophosphatemia with increased renal phosphate wasting, normal serum calcium, 1,25(OH)2D and parathyroid hormone (PTH), and mild elevation of serum FGF23. No mutation was detected in the genes known to cause HR such as PHEX, FGF23, DMP1, ENPP1, CLCN5, SGK3, FAM20C, SLC9A3R1, SLC34A1 or SLC34A3 by exome sequencing. A heterozygous variant c.448 C>T (p.Arg150Cys) in the PTH1R gene was found in the patient, his unaffected father and 5 siblings. The same heterozygous variant was previously reported in human enchondromatosis and caused enchondroma-like lesions in transgenic mice. A large heterozygous deletion of more than 7 Kb in the SGK3 distal promoter was identified in the patient by whole genome sequencing. Conclusions: SGK3 distal promoter deletion is likely the candidate gene causing the disease. PTH1R Arg150Cys variant may contribute to the disease phenotype. SGK3 promoter deletion should be considered in patients with late-onset genetic hypophosphatemic rickets.

  • Open Access

    Molecular Genetics of 1α-Hydroxylase Deficiency in the Saudi Population

    by Bassam Bin-Abbas, Afaf Alsagheir, Balgees Alghamdi, Allianah Benito, Yufei Shi, Somaya Khader Alzelaye, Noman Ahmad, Fahad Al Juraibah, Amer Omar Alali, Adnan Al Shaikh, et al.

    Context: The aim of this study was to characterize the molecular genetics of 1α-hydroxylase deficiency in the highly consanguineous population of Saudi Arabia, hypothesizing that the results will show a unique CYP27B1 genotype. Methods: We collected data on a large cohort of patients diagnosed with 1α-hydroxylase deficiency from different parts of the country. These patients underwent molecular testing for CYP27B1 mutations. Results: A cohort of 45 patients from 29 unrelated families was studied. In 13 families (29 patients), more than one affected sibling was included (2-4 siblings) while the other 16 families had only a single patient per family. The patients included 24 females and 21 males with median age at time of presentation of 1 year and a current median age of 10 years. The clinical, biochemical and radiological profile was typical of 1α-hydroxylase deficiency. Molecular testing showed 10 mutations of different types in the 29 families. Four mutations were novel (p.(Trp257LeufsTer76), p.(Glu101Gln), p.(Gly398Ser), and p.(Arg206Cys)) while the other 6 mutations were previously described (p.(arg429Pro), p.(Phe443Profs*24), p.(Gln135Ter), p. (Gly102Glu), p.(Gln504Ter), and c.589 + 1G > A). Two of the previously reported mutations were from Saudi patients and have never been reported from other populations, increasing the number of novel/previously novel mutations to 6 of 10 mutations (60%). The most common mutation was c.1286G > C, p.(Arg429Pro) occurring in 22 patients from 15 unrelated families (51.7%). Conclusion: The molecular genetics of 1α-hydroxylase deficiency in Saudi Arabia is unique with several novel mutations of different types and a possible founder mutation.


  • Open Access

    Identification of novel prognostic biomarkers for thyroid cancer by integrated transcriptome analysis of metastasis-associated genes

    by Bushra Alnwisser, Salman Alshehri, Amal Qattan, Minjing Zou, Abdelilah Aboussekhra, Ali S. Alzahrani, Yufei Shi

    Introduction: Distant metastasis (DM) is the most important prognostic factor affecting the overall survival (OS) of thyroid cancer. The current study aimed to discover prognostic biomarkers to predict thyroid cancer survival, particularly papillary thyroid carcinoma (PTC), the most common subtype of thyroid cancer.Methods: Four RNA sequencing (RNA-Seq) datasets of experimental lung metastasis from four transgenic mouse models of PTC, follicular thyroid cancer (FTC), poorly differentiated thyroid cancer (PDTC), and anaplastic thyroid cancer (ATC) were integrated to screen for candidate genes involved in DM. The Cancer Genome Atlas-Thyroid Cancer (TCGA-THCA) dataset was used to validate the candidate genes.Results: A total of 105 upregulated and 25 downregulated differentially expressed genes (DEGs) were identified to be present in all four datasets. Regulation of cytokine production, inflammation, immune checkpoint regulation, and MAPK/ERK cascade were major enriched pathways in metastatic tumor cells. Seven genes were identified whose overexpression was present in 63 of 498 PTC patients (13%) and was associated with poor OS (p < 0.01). Clinically, the seven-gene expression signature was associated with older age at the diagnosis, late stage of tumor, tall cell variant, and higher aneuploidy and hypoxia score. Mutation load was increased in patients with seven-gene expression signature: 26 samples had more than one driver mutation (47%, 26/55). Deep deletions in other chromosomal loci were frequently found in patients with BRAFV600E mutations. In contrast, only 7% of patients without a seven-gene expression signature had more than one driver mutation (24/243). Increased chromosomal instability was also observed in patients with a seven gene expression signature.Conclusion: The seven-gene expression signature is associated with poor prognosis and chromosomal instability. These genes may be useful biomarkers for risk stratification for DM and help decision-making in initial surgical recommendations.


  • Open Access

    Genome-wide transcriptome analysis and drug target discovery reveal key genes and pathways in thyroid cancer metastasis

    by Minjing Zou, Amal Qattan, Monther Al-Alwan, Hazem Ghebeh, Naif Binjumah, Latifa Al-Haj, Khalid S. A. Khabar, Abdulmohsen Altaweel, Falah Almohanna, Abdullah M. Assiri, et al.

    Introduction: Metastasis is the major cause of thyroid cancer morbidity and mortality. However, the mechanisms are still poorly understood. Methods: We performed genome-wide transcriptome analysis comparing gene expression profile of metastatic thyroid cancer cells (Met) with primary tumor cells established from transgenic mouse models of papillary thyroid cancer (PTC), follicular thyroid cancer (FTC), poorly differentiated thyroid cancer (PDTC), and anaplastic thyroid cancer (ATC).Results: Genes involved in tumor microenvironment (TME), inflammation, and immune escape were significantly overexpressed in Met cells. Notably, IL-6-mediated inflammatory and PD-L1 pathways were highly active in Met cells with increased secretion of pro-inflammatory and pro-metastatic cytokines such as CCL2, CCL11, IL5, IL6, and CXCL5. Furthermore, Met cells showed robust overexpression of Tbxas1, a thromboxane A synthase 1 gene that catalyzes the conversion of prostaglandin H2 to thromboxane A2 (TXA2), a potent inducer of platelet aggregation. Application of aspirin, a TXA2 inhibitor, significantly reduced lung metastases. Mertk, a member of the TAM (Tyro, Axl, Mertk) family of RTKs, was also overexpressed in Met cells, which led to increased MAPK activation, epithelial–mesenchymal transition (EMT), and enrichment of cancer stem cells. Braf-mutant Met cells developed resistance to BRAFV600E inhibitor PLX4720, but remained sensitive to β-catenin inhibitor PKF118-310.Conclusion: We have identified several overexpressed genes/pathways in thyroid cancer metastasis, making them attractive therapeutic targets. Given the complexity of metastasis involving multiple pathways (PD-L1, Mertk, IL6, COX-1/Tbxas1-TXA2), simultaneously targeting more than one of these pathways may be warranted to achieve better therapeutic effect for metastatic thyroid cancer.


  • Low emissivity and thermal insulating infrared stealth composite of silver plating TPU fibers@WPU/CNF aerogel with all-in-one structure

    by Tao Zhang, Wanqi Feng, Yixiang Chen, Yufei Shi, Ze Chen, Dan Yu, Wei Wang


  • Open Access

    β-catenin attenuation leads to up-regulation of activating NKG2D ligands and tumor regression in BrafV600E-driven thyroid cancer cells

    by Minjing Zou, Suhad Al-Yahya, Monther Al-Alwan, Huda A. BinEssa, Khalid S. A. Khabar, Falah Almohanna, Abdullah M. Assiri, Abdulmohsen Altaweel, Amal Qattan, Brian F. Meyer, et al.

    Introduction: BRAFV600E mutations frequently occur in papillary thyroid cancer (PTC). β-catenin, encoded by CTNNB1, is a key downstream component of the canonical Wnt signaling pathway and is often overexpressed in PTC. BRAFV600E-driven PTC tumors rely on Wnt/β-catenin signaling to sustain growth and progression.Methods: In the present study, we investigated the tumorigenicity of thyroid cancer cells derived from BRAFV600E PTC mice following Ctnnb1 ablation (BVE-Ctnnb1null).Results: Remarkably, the tumorigenic potential of BVE-Ctnnb1null tumor cells was lost in nude mice. Global gene expression analysis of BVE-Ctnnb1null tumor cells showed up-regulation of NKG2D receptor activating ligands (H60a, H60b, H60c, Raet1a, Raet1b, Raet1c, Raet1d, Raet1e, and Ulbp1) and down-regulation of inhibitory MHC class I molecules H-2L and H-2K2 in BVE-Ctnnb1null tumor cells. In vitro cytotoxicity assay demonstrated that BVE-Ctnnb1wt tumor cells were resistant to NK cell-mediated cytotoxicity, whereas BVE-Ctnnb1null tumor cells were sensitive to NK cell-mediated killing. Furthermore, the overexpression of any one of these NKG2D ligands in the BVE-Ctnnb1wt cell line resulted in a significant reduction of tumor growth in nude mice. Conclusions: Our results indicate that active β-catenin signaling inhibits NK cell-mediated immune responses against thyroid cancer cells. Targeting the β-catenin signaling pathway may have significant therapeutic benefits for BRAF-mutant thyroid cancer by not only inhibiting tumor growth but also enhancing host immune surveillance.


  • Open Access

    Fig. S2 from β-Catenin Attenuation Inhibits Tumor Growth and Promotes Differentiation in a BRAFV600E-Driven Thyroid Cancer Animal Model

    by Minjing Zou, Huda A. BinEssa, Yousif H. Al-Malki, Suhad Al-Yahya, Monther Al-Alwan, Ibrahim Al-Jammaz, Khalid S.A. Khabar, Falah Almohanna, Abdullah M. Assiri, Brian F. Meyer, et al.

    Fig. S2. Kdm4a expression in thyroid tumor samples and cell lines. Kdm4a expression was analyzed by RNA-Seq. in normal control thyroids, BVE-Ctnnb1wt (BVE) and BVE-Ctnnb1null thyroid tumors, and cell lines. * indicates statistically significant between normal and tumor samples or cell lines (p<0.01). Data are expressed as mean {plus minus} SEM.

  • Open Access

    Data from β-Catenin Attenuation Inhibits Tumor Growth and Promotes Differentiation in a BRAFV600E-Driven Thyroid Cancer Animal Model

    by Minjing Zou, Huda A. BinEssa, Yousif H. Al-Malki, Suhad Al-Yahya, Monther Al-Alwan, Ibrahim Al-Jammaz, Khalid S.A. Khabar, Falah Almohanna, Abdullah M. Assiri, Brian F. Meyer, et al.

    BRAFV600E mutation is the most frequent genetic alteration in papillary thyroid cancer (PTC). β-Catenin (Ctnnb1) is a key downstream component of canonical Wnt signaling pathway and is frequently overexpressed in PTC. BRAFV600E-driven tumors have been speculated to rely on Wnt/β-catenin signaling to sustain its growth, although many details remain to be elucidated. In this study, we investigated the role of β-catenin in BrafV600E-driven thyroid cancer in a transgenic mouse model. In BrafV600E mice with wild-type (WT) Ctnnb1 (BVE-Ctnnb1WT or BVE), overexpression of β-catenin was observed in thyroid tumors. In BrafV600E mice with Ctnnb1 knockout (BVE-Ctnnb1null), thyroid tumor growth was slowed with significant reduction in papillary architecture. This was associated with increased expression of genes involved in thyroid hormone synthesis, elevated 124iodine uptake, and serum T4. The survival of BVE-Ctnnb1null mice was increased by more than 50% during 14-month observation. Mechanistically, downregulation of MAPK, PI3K/Akt, and TGFβ pathways and loss of epithelial–mesenchymal transition (EMT) were demonstrated in the BVE-Ctnnb1null tumors. Treatment with dual β-catenin/KDM4A inhibitor PKF118–310 dramatically improved the sensitivity of BVE-Ctnnb1WT tumor cells to BRAFV600E inhibitor PLX4720, resulting in significant growth arrest and apoptosis in vitro, and tumor regression and differentiation in vivo. These findings indicate that β-catenin signaling plays an important role in thyroid cancer growth and resistance to BRAFV600E inhibitors. Simultaneously targeting both Wnt/β-catenin and MAPK signaling pathways may achieve better therapeutic outcome in BRAFV600E inhibitor-resistant and/or radioiodine-refractory thyroid cancer.

  • Open Access

    Data from β-Catenin Attenuation Inhibits Tumor Growth and Promotes Differentiation in a BRAFV600E-Driven Thyroid Cancer Animal Model

    by Minjing Zou, Huda A. BinEssa, Yousif H. Al-Malki, Suhad Al-Yahya, Monther Al-Alwan, Ibrahim Al-Jammaz, Khalid S.A. Khabar, Falah Almohanna, Abdullah M. Assiri, Brian F. Meyer, et al.

    BRAFV600E mutation is the most frequent genetic alteration in papillary thyroid cancer (PTC). β-Catenin (Ctnnb1) is a key downstream component of canonical Wnt signaling pathway and is frequently overexpressed in PTC. BRAFV600E-driven tumors have been speculated to rely on Wnt/β-catenin signaling to sustain its growth, although many details remain to be elucidated. In this study, we investigated the role of β-catenin in BrafV600E-driven thyroid cancer in a transgenic mouse model. In BrafV600E mice with wild-type (WT) Ctnnb1 (BVE-Ctnnb1WT or BVE), overexpression of β-catenin was observed in thyroid tumors. In BrafV600E mice with Ctnnb1 knockout (BVE-Ctnnb1null), thyroid tumor growth was slowed with significant reduction in papillary architecture. This was associated with increased expression of genes involved in thyroid hormone synthesis, elevated 124iodine uptake, and serum T4. The survival of BVE-Ctnnb1null mice was increased by more than 50% during 14-month observation. Mechanistically, downregulation of MAPK, PI3K/Akt, and TGFβ pathways and loss of epithelial–mesenchymal transition (EMT) were demonstrated in the BVE-Ctnnb1null tumors. Treatment with dual β-catenin/KDM4A inhibitor PKF118–310 dramatically improved the sensitivity of BVE-Ctnnb1WT tumor cells to BRAFV600E inhibitor PLX4720, resulting in significant growth arrest and apoptosis in vitro, and tumor regression and differentiation in vivo. These findings indicate that β-catenin signaling plays an important role in thyroid cancer growth and resistance to BRAFV600E inhibitors. Simultaneously targeting both Wnt/β-catenin and MAPK signaling pathways may achieve better therapeutic outcome in BRAFV600E inhibitor-resistant and/or radioiodine-refractory thyroid cancer.

  • Open Access

    Fig. S1 from β-Catenin Attenuation Inhibits Tumor Growth and Promotes Differentiation in a BRAFV600E-Driven Thyroid Cancer Animal Model

    by Minjing Zou, Huda A. BinEssa, Yousif H. Al-Malki, Suhad Al-Yahya, Monther Al-Alwan, Ibrahim Al-Jammaz, Khalid S.A. Khabar, Falah Almohanna, Abdullah M. Assiri, Brian F. Meyer, et al.

    Fig. S1. Up-regulation of thyroid hormone synthesis-related genes in the BVE-Ctnnb1null thyroid tumors. Data are expressed as fold changes between BVE-Ctnnb1null and BVE tumors.